论文部分内容阅读
目的:观察并比较普伐他汀和低分子肝素对肾病综合征高凝状态的影响。方法:经尾静脉一次性注入阿霉素(2%的阿霉素,6.5 mg.kg-1)制作肾病综合征模型,观察普伐他汀、低分子肝素及联合用药对血浆凝血与纤溶分子标志物抗凝血酶Ⅲ、D-二聚体和纤维蛋白原的影响。结果:普伐他汀和低分子肝素均可使血浆D-二聚体含量下降,普伐他汀可使肾病模型大鼠的抗凝血酶Ⅲ水平明显升高,而低分子肝素组抗凝血酶Ⅲ水平与模型组差异无统计学意义,三个治疗组的纤维蛋白原浓度、血液生化指标与模型组差异均没有统计学意义。结论:阿霉素诱导的大鼠肾病综合征可出现明显的高凝状态,普伐他汀明显升高血浆ATⅢ水平,改善肾病综合征大鼠高凝状态。
Objective: To observe and compare the effect of pravastatin and low molecular weight heparin on hypercoagulability of nephrotic syndrome. Methods: A nephrotic syndrome model was established by injecting doxorubicin (2% doxorubicin, 6.5 mg.kg-1) into the tail vein at once. The effects of pravastatin, low molecular weight heparin and combination therapy on plasma coagulation and fibrinolysis Effects of markers antithrombin III, D-dimer and fibrinogen. Results: Both pravastatin and low molecular weight heparin could decrease the plasma D-dimer level. Pravastatin increased the level of antithrombin Ⅲ in nephropathy rats, while low molecular weight heparin group showed antithrombin Ⅲ level and the model group was no significant difference in the three treatment groups fibrinogen concentration, blood biochemical indicators and the model group differences were not statistically significant. CONCLUSION: Adriamycin-induced rat nephrotic syndrome may show hypercoagulable state. Pravastatin significantly increases plasma ATⅢ level and improves hypercoagulability in rats with nephrotic syndrome.